Roth MKM Reiterates Buy on Fortress Biotech, Raises Price Target to $16
Fortress Biotech Analyst Ratings
Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical
Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY
Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY
Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY
Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 If Cosibelimab If Approved in EU Prior to Certain Deadlines >524715.BY
Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY
Press Release: Sun Pharma to Acquire Checkpoint Therapeutics
Express News | Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (Dfd-29) to Treat Rosacea
Mustang Bio Stock Plunges 29% on Lease Termination News
Mustang Bio Exits Lease Of Manufacturing Facility; Co Expects Savings Of ~$2M
Express News | Mustang Bio Inc - to Initiate Clinical Trial With Mb-109 for GBM in H2 2025
Express News | Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
Express News | Mustang Bio Regains Compliance With Nasdaq Minimum Bid Price Requirement
Express News | Mustang Bio Announces Pricing of $8 Million Public Offering
Fortress Biotech Advances Triplex Vaccine To Trial Stage With First Patient Dosed
Express News | Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce Cmv Events in Recipients of Hsct
Loungers Agrees to Improved $433 Mln Fortress Takeover
Express News | Mustang Bio Announces Reverse Stock Split
Unlock the Full List